Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model

Client Compensation:

Once enrolled, all trial-related procedures will be covered in addition to $800 upon completion of the trial.

Potential Medical Benefits: 

This study examines new therapeutic approach for soft tissue sarcomas that use the immune system to attack the cancer. Your dog might benefit from this new therapy that is aimed to control the local and metastatic disease and prolong life.

Potential Medical Risks: 

The risk of adverse effects with the therapies in this trial is low but still possible.  Injection of the anti-MIC antibody and NK cells may cause infection, anaphylactic shock, collapse, anorexia, vomiting, diarrhea, and, in extreme situations, even death. It is possible that your dog's condition may not improve, or it may worsen or even die. Your dog will be observed closely for side effects, and appropriate medical care will be provided if needed.

What qualifies my pet for enrollment?

Inclusion Criteria: 
The following dogs may be included in the Trial: 
•    Dogs that are otherwise healthy with localized cytologically or histologically confirmed soft tissue sarcoma will be recruited to the trial.

Exclusion Criteria: 
The following dogs will be excluded from the trial:
•    Dogs with a history of immune deficiency or requiring immunosuppressive medications will be excluded.
•    Dogs received local radiation therapy to the primary tumor before the study intervention.  

Diagnosis/Condition Being Studied: 
Canine Soft Tissue Sarcomas

Intervention to Be Studied: 
Injection of MIC antibody and infusion of immune cells (Natural killer cells expanded from the tumor and reinjected to patient)